Firstly, this highlight the need for service improvement to ensure that adherence is regularly monitored. Those who are non-adherent can be referred to the RASP study or for inhaled nitric oxide (FeNO) monitoring. Secondly, patients on long-term OCS may be prevented from benefiting from the steroid sparing effects of mepolizumab. To achieve the necessary eosinophil counts steroids must be progressively reduced risking destabilisation of asthma control. Introduction and Objectives In asthma, seasonal variation in outcomes is known with seasonal peaks in exacerbation. Allergic inflammation is associated with greater susceptibility to viral infections. The UK real world studies, APEX I and II, demonstrated omalizumab reduced exacerbation frequency, healthcare utilisation, OCS burden and improved lung function in severe allergic asthma patients, but initial analyses excluded an assessment of seasonal impact. Patients initiated during their usual symptom season, may have inadequate time to suppress basophils and mast cells prior to exacerbating and consequently fail their 16 week treatment assessment assessing response. The objective was to determine if season/month of initiation had any impact on response (16 week clincial assessment according to usual clinical practice at each centre), hospital (A and E attendance and/or admission) and 'dose exacerbation', (OCS dose increase 10 mg for 3 days) rates. Methods The APEX II data was reanalysed, directly comparing response rate and frequency of exacerbations with time of initiation. We also looked at the pattern of seasonal exacerbations pre-and post-omalizumab initiation. Results In the 258 cases included, response rate at 16 weeks where response was known was 82.4%. Highest response rates were in those initiated on treatment in December (90%) and July (89%) and lowest were January (62%) and August (69%). The total number of 'hospital exacerbations', over the 12 month period pre-and post-initiation was reduced from 362 to 151. Pre-initiation, there was a seasonal peak of hospital exacerbations (figure 1) from August to October. This was suppressed by omalizumab, with greatest reduction observed in September (76%) and lowest in March (29%). The total number of 'dose exacerbations', over the 12 month period preand post-initiation was reduced from 948 to 522. The seasonal pattern was different than for hospital admissions, with a relatively consistent reduction of dose exacerbations across the year. The season/month of initiation was not statistically different for response, hospital and dose exacerbation rates. Conclusions Regardless of the timing of initiation, the response rate to omalizumab is consistent through the year, the biggest observable seasonal effect, was the diminishing of the seasonal peak of hospital exacerbations around early autumn.
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Abstract P19 Figure 1 Impact of omalizumab on hospital exacerbations. 2 point moving average is the average of the previous data point and the current data point.
P20 LATENT HELMINTH DISEASE AS A CAUSE OF EOSINOPHILIA IN RESPIRATORY PATIENTS
Introduction Within the UK, eosinophilia is most commonly associated with allergy and respiratory diseases such as asthma. Increasingly raised blood eosinophil counts are seen as a biomarker of heightened Th2 inflammation indicating a need to prescribe steroids in airways diseases. New treatments for severe Th2-high asthma aim to inhibit the eosinophilic pathway to reduce pathological inflammation. However by inhibiting this pathway we risk suppressing the body's natural defences against parasitic helminth disease -in patients with asymptomatic latent Strongyloides stercoralis there is the risk of catastrophic hyper-infection. Our particular patient cohort in East London is a diverse international community who travel frequently. We therefore sought to evaluate the prevalence of asymptomatic helminth disease in respiratory, and particularly asthma patients, within our Trust, which includes a severe asthma service where we prescribe biologics that inhibit the Th2 pathway. Methods We prospectively tested eosinophilic patients reviewed in respiratory clinic for helminth infection using serological screening as part of a Service Evaluation. Inclusion criteria were an eosinophilia (0.3) or those being considered for treatment with Mepoluzimab. Patients were tested for strongyloidiasis, filariasis and schistosomiasis depending on travel history. Patients symptomatic of helminth infection (e.g., diarrhoea) were excluded from this evaluation. Results We tested 80 patients, 32 from severe asthma clinic, 42 from the general asthma clinic and 6 from other clinics. From these 16 (20%) had positive parasite serology: 14 of these were for Strongyloides stercoralis and 1 each for filarial and schistosomal. All the positives had asthma and 4 were from the severe asthma service. The average IgE was 433 and the average eosinophil count was 0.7. There was no statistical difference between the eosinophil counts, or total IgEs, between the positive and negative groups. Conclusion There is a high prevalence of asymptomatic parasitic infection within our cohort, suggesting local patients who have an eosinophilia should be screened for helminth disease even in the presence of another cause eosinophilia. Furthermore, we recommend all patients being assessed for a biologic that would inhibit Th2 responses, such as Mepoluzimab, should be screened for latent Stronglyloides stercoralis infection given the danger of hyper-infection upon immunosuppression. Steroid insensitivity and the heterogeneous nature of asthma represent a significant clinical challenge for patients with severe asthma. The use of peripheral blood mononuclear cells (PBMC) in recent studies has allowed researchers to demonstrate that poor steroid response could be due to corticosteroid insensitivity in immune cells. These cells have been used as a model to investigate the underlying molecular mechanisms of corticosteroid resistance. These models were however inconclusive and have failed to consider asthma phenotypes. Our aim was to determine in vitro corticosteroid sensitivity of isolated PBMCs in T H 2 high and T H 2 low patients. Severe asthma patients as classified by the Global Initiative for Asthma were recruited and divided into T H 2 high and T H 2 low cohorts based on fractional exhaled nitric oxide (FeNO). Isolated PBMCs were stimulated with aCD3/28 alone or in the presence of dexamethasone (10 -10 M-10 -6 M). IL-5, IL-13 and IL-17 cytokine release were measured using ELISA. Correlation studies were carried out to determine whether the LogIC 50 or FeNO correlated with markers of asthma severity. PBMCs stimulated with aCD3/28 showed significant IL-5 and IL-17 release in T H 2 low but not T H 2 high patients. Production of IL-5 or IL-7 was dose-dependently suppressed by dexamethasone with different potencies. IL-13 was only significantly stimulated in T H 2 low patients and did not show suppression by dexamethasone. A significant negative correlation between aCD3/28 stimulated IL-17 production and FeNO was observed. Overall, PBMCs from severe asthmatics retain cell responsiveness to TCR engagement with production of T H 2 and T H 17 cytokines and inhibition by dexamethasone. Additional studies comparing T H 2 high vs T H 2 low patients are required to determine whether differences in in vitro CS response exist between these 2 categories of patients.
